FDA Okays Bristol-Myers Opdivo-Yervoy Combo for Cancer Treatment

FDA approved the combination of OPDIVO plus YERVOY as first-line treatment for patients with metastatic non-small cell lung cancer whose tumors express PD-L1(≥1%).

• FDA also approved Agilent Technologies’s PD-L1 IHC 28-8 pharmDx as a companion diagnostic device for selecting patients with NSCLC for treatment with the combo by Bristol-Myers

To view the source of this information click here

To contact the reporter on this story:
Linly Lin in San Francisco at llin153@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2020 Bloomberg L.P. All rights reserved. Used with permission.